Who Owns Lineage Cell Therapeutics Stock?
NYSE: LCTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 48.30%
- Held by insiders
- 4.86%
- Institutional holders
- 183
- Institutions 48.3%
- Insiders 4.9%
- Public and other 46.8%
Who owns Lineage Cell Therapeutics stock?
Institutional investors own about 48.3% of Lineage Cell Therapeutics's shares, spread across 183 institutions that file 13F reports. That level of institutional ownership is moderate. Insiders, including executives, directors and large founding shareholders, hold 4.86% of LCTX.
The largest institutional holders are Broadwood Capital, Inc. (19.59%), Blackrock Inc. (5.48%) and Vanguard Capital Management LLC (3.47%). Together, the top 10 institutions control 40.3% of shares outstanding. In their latest filings, 6 of the top 10 institutions increased their LCTX positions and 2 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of LCTX
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Broadwood Capital, Inc. | 49.56M | 19.59% | 0.0% |
| Blackrock Inc. | 13.87M | 5.48% | +5.2% |
| Vanguard Capital Management LLC | 8.78M | 3.47% | -3.1% |
| Defender Capital, LLC | 6.65M | 2.63% | +0.8% |
| Geode Capital Management, LLC | 5.34M | 2.11% | +0.8% |
| Raffles Associates Lp | 5.20M | 2.05% | 0.0% |
| Fifth Third Bancorp | 4.90M | 1.94% | +6.5% |
| Millennium Management Llc | 3.02M | 1.19% | -45.7% |
| State Street Corporation | 2.93M | 1.16% | +26.4% |
| Vanguard Fiduciary Trust Co | 1.72M | 0.68% | +2.8% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of LCTX
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 5.91M | 2.34% |
| iShares Trust-iShares Russell 2000 ETF | 4.51M | 1.78% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 2.96M | 1.17% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.99M | 0.79% |
| iShares Trust-iShares Russell 2000 Growth ETF | 1.75M | 0.69% |
| iShares Trust-iShares Biotechnology ETF | 1.46M | 0.58% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 1.20M | 0.48% |
| VANGUARD SCOTTSDALE FUNDS-Vanguard Russell 2000 Index Fund | 1.05M | 0.42% |
| iShares Trust-iShares Micro-Cap ETF | 581.34K | 0.23% |
| SCHWAB CAPITAL TRUST-Schwab Small-Cap Index Fund | 447.53K | 0.18% |
Frequently asked questions
Who is the largest shareholder of Lineage Cell Therapeutics?
Broadwood Capital, Inc. is the largest institutional shareholder of LCTX, owning 19.59% of shares outstanding (49.56M shares) as of its latest 13F filing.
What percentage of Lineage Cell Therapeutics is owned by institutions?
Institutions own about 48.3% of LCTX shares and 50.8% of the public float.
How much of Lineage Cell Therapeutics do insiders own?
Insiders, such as officers and directors, own about 4.86% of LCTX shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.